Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Pennsylvania Business Bulletin.
Press releases published on May 22, 2025
Railey Molinario Relationship Intelligence Expert Unveils RI, a Scalable Framework for Building Stronger Human Connections
GlobeNewswire
·
May 22, 2025
London, UK, May 22, 2025 (GLOBE NEWSWIRE) -- Renowned relationship coaching firm Railey Molinario Relationship Intelligence Expert today announced the official launch of RI™️, a pioneering framework designed to help individuals, couples and organizations …
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
GlobeNewswire
·
May 22, 2025
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, …
FAST TRACK GROUP Announces Pricing of $15 Million Initial Public Offering
GlobeNewswire
·
May 22, 2025
SINGAPORE, May 22, 2025 (GLOBE NEWSWIRE) -- FAST TRACK GROUP (“Fast Track” or the “Company”), a leading entertainment-focused event management and celebrity agency company, announced the pricing of its initial public offering of 3,750,000 ordinary shares ( …
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 22, 2025
– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd – – Encore presentation planned at EHA 2025 Congress – – Kura Oncology to host virtual investor event at 7:30pm …
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
May 22, 2025
Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab as 1L treatment of r/ …
RCF Opportunities Fund II L.P. Files Early Warning Report Regarding Common Shares of Defense Metals Corp.
GlobeNewswire
·
May 22, 2025
DENVER, May 22, 2025 (GLOBE NEWSWIRE) -- RCF Opportunities Fund II L.P. (“RCF”) reports that it has filed an early warning report under National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in respect …
Abcourt annonce ses résultats du troisième trimestre terminé le 31 mars 2025
GlobeNewswire
·
May 22, 2025
ROUYN-NORANDA, Québec, 22 mai 2025 (GLOBE NEWSWIRE) -- Mines Abcourt Inc. (« Abcourt » ou la « Société ») (TSX Venture: ABI) (OTCQB : ABMBF) annonce ses résultats du troisième trimestre terminé le 31 mars 2025. Toutes les valeurs monétaires dans ce …
IMUNON Announces Withdrawal of Form S-1 Registration Statement
GlobeNewswire
·
May 22, 2025
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and …
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
GlobeNewswire
·
May 22, 2025
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
Daktronics to Participate in the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28th
GlobeNewswire
·
May 22, 2025
BROOKINGS, S.D., May 22, 2025 (GLOBE NEWSWIRE) -- Daktronics, Inc. (Nasdaq: DAKT), a leading global designer and manufacturer of best-in-class dynamic video communication displays and control systems for customers worldwide today announced that Brad …
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
GlobeNewswire
·
May 22, 2025
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025 ICT01 in combination with azacitidine and venetoclax (Aza-Ven) achieves unprecedented high remission rates overall and across molecular subtypes in newly …
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
GlobeNewswire
·
May 22, 2025
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b …
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
GlobeNewswire
·
May 22, 2025
An oral presentation at ASCO …
ROHM Develops Compact Surface-Mount Near-Infrared LEDs Featuring Industry-Leading Radiant Intensity
GlobeNewswire
·
May 22, 2025
Santa Clara, CA and Kyoto, Japan, May 22, 2025 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced an expanded portfolio of surface-mount near-infrared (NIR) LEDs with new compact top-view types optimized for applications such as VR/AR devices, …
Lynch Carpenter Investigates Claims in Kettering Health Data Breach
GlobeNewswire
·
May 22, 2025
PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Kettering Health (“Kettering”) recently announced a cybersecurity incident that resulted in the disruption of their network operations across. Details about the approximate number of people affected and the …
Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
GlobeNewswire
·
May 22, 2025
· BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/ …
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
May 22, 2025
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer …
Petrus Announces Results of Annual General Meeting of Shareholders
GlobeNewswire
·
May 22, 2025
CALGARY, Alberta, May 22, 2025 (GLOBE NEWSWIRE) -- Petrus Resources Ltd. ("Petrus" or the "Company") (TSX: PRQ) is pleased to announce that its shareholders approved all resolutions at its annual general meeting of shareholders held yesterday (the "Meeting …
Acceleware Ltd. Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 22, 2025
CALGARY, Alberta, May 22, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), an advanced electromagnetic (“EM”) heating company with highly scalable solutions for large industrial applications, today announced its …
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
GlobeNewswire
·
May 22, 2025
Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at …